## 1 Free cortisol and free 21-deoxycortisol in the clinical evaluation of congenital

# 2 adrenal hyperplasia

3 Bas P.H. Adriaansen<sup>1,2\*</sup>, Agustini Utari<sup>3</sup>, André J. Olthaar<sup>1</sup>, Rob C.B.M. van der Steen<sup>1</sup>, Karijn J.

- 4 Pijnenburg-Kleizen<sup>4</sup>, Lizanne Berkenbosch<sup>2,5</sup>, Paul N. Span<sup>6</sup>, Fred C.G.J. Sweep<sup>1</sup>, Hedi L. Claahsen-van
- 5 der Grinten<sup>2†</sup>, Antonius E. van Herwaarden<sup>1†</sup>
- 6 <sup>†</sup> These authors contributed equally to this work and share last authorship
- 7

8 <sup>1</sup>Radboud university medical center, Department of Laboratory Medicine, Nijmegen, the 9 Netherlands; <sup>2</sup>Amalia Children's hospital, Radboud university medical center, Department of 10 Pediatrics, Division of Pediatric Endocrinology, Nijmegen, the Netherlands; <sup>3</sup>Diponegoro University, 11 Division of Pediatric Endocrinology, Department of Pediatrics, Faculty of Medicine, Semarang, 12 Indonesia; <sup>4</sup>Canisius Wilhelmina hospital, Department of Pediatrics, Nijmegen, the Netherlands; 13 <sup>5</sup>MosaKids Children's hospital, Maastricht University Medical Centre+, Department of Pediatrics, 14 Division of pediatric Endocrinology, Maastricht, the Netherlands; <sup>6</sup>Radboud university medical center, Department of Radiation Oncology, Nijmegen, the Netherlands 15

16

17 Keywords: ACTH, CAH, cortisol, free cortisol, 21-deoxycortisol, free 21-deoxycortisol

18

### 19 \*Corresponding author

- 20 Bas P.H. Adriaansen
- 21 Radboud university medical Center
- 22 Department of Pediatrics
- 23 Geert Grooteplein Zuid 10 (huispost 804)
- 24 Postbus 9101, 6500HB
- 25 Nijmegen, Gelderland, the Netherlands
- 26 Tel: +31 (0)24 361 4430
- 27 E-mail address: <u>Bas.Adriaansen@radboudumc.nl</u>
- 28 ORCID: 0000-0003-1439-236X
- 29
- 30 Funding
- 31 This work was funded by International Fund Congenital Adrenal Hyperplasia (IFCAH).
- 32
- 33 Disclosures
- 34 The authors have nothing to disclose.

### 35 Abstract

36 Context: Some patients with classic congenital adrenal hyperplasia (CAH) survive without 37 glucocorticoid treatment. Increased precursor concentrations in these patients might lead to higher 38 free (biological active) cortisol concentrations by influencing the cortisol-protein binding. In 21-39 hydroxylase deficiency (210HD), the most common CAH form, accumulated 21-deoxycortisol (21DF), 40 a precursor steroid, may further increase glucocorticoid activity. Both mechanisms could explain the 41 low occurrence of symptoms in some untreated classic CAH patients. 42 Objective: Establishment and validation of an LC-MS/MS method for (free) cortisol and (free) 21DF to 43 quantify these steroids in untreated patients with classic CAH (n=29), non-classic CAH (NCCAH, n=5), 44 other forms of adrenal insufficiency (AI, n=3), and controls (n=11) before and 60 minutes after 45 Synacthen<sup>®</sup> administration. 46 *Results*: Unstimulated total cortisol levels of untreated classic CAH patients (median 109 nmol/L) 47 were lower compared to levels in untreated NCCAH patients (249 nmol/L, p=0.010) and controls (202 48 nmol/L, p=0.016), but free cortisol concentrations were similar. Basal free 21DF levels were high in 49 210HD patients (median 5.32 nmol/L) and undetectable in Al patients and controls (<0.19 nmol/L).

After Synacthen<sup>®</sup> administration, free concentrations of 21DF -but not cortisol- increased only in
 patients with 210HD.

52 <u>Conclusions:</u> Free cortisol levels were similar in classic CAH compared to controls and NCCAH 53 patients, suggesting a comparable availability of cortisol. Additionally, 210HD patients produce high 54 levels of the glucocorticoid 21DF, possibly explaining the low occurrence of symptoms in some classic 55 210HD patients. Free cortisol and (free) 21DF levels should be considered in the clinical evaluation of 56 adrenal insufficiency in patients with CAH.

57

#### 58 Introduction

Glucocorticoids, like cortisol, are among others essential for maintaining blood pressure, glucose metabolism, and modulating the immune response [1, 2]. Cortisol is produced by the adrenal cortex and has a diurnal rhythm with the highest concentration in the early morning [3]. The hypothalamus regulates this rhythm by stimulating the pituitary gland, which subsequently produces adrenocorticotropic hormone (ACTH). Negative feedback by cortisol balances the activity of the hypothalamus-pituitary-adrenal (HPA) axis. During periods of physical stress, such as infection or surgery, the demand for cortisol increases, which is mediated by an increased ACTH release.

Patients with primary adrenal insufficiency (PAI) have insufficient cortisol production and are unable to increase cortisol levels during periods of stress. This leads to symptoms of cortisol deficiency such as extreme fatigue, weight loss, and abdominal pain. In adults, PAI is most often caused by acquired conditions such as auto-immune adrenalitis, known as Addison's disease. In children, PAI is generally 70 caused by inherited conditions affecting adrenal steroid production. The most common inherited 71 form of PAI is classic congenital adrenal hyperplasia (CAH) caused by an enzyme deficiency in the 72 adrenal steroidogenesis pathway. Most CAH patients have 21-hydroxylase deficiency (210HD) (90 -73 95%) or 11-hydroxylase deficiency (11-OHD) ( $\sim$ 5%). These patients have insufficient cortisol 74 production and consequently, a reduced negative feedback to the pituitary gland, causing chronically 75 elevated ACTH levels. This leads to continuous activation of the adrenal cortex and accumulation of 76 precursor steroids before the enzymatic block. These precursor steroids are partly shunted into the 77 unaffected adrenal androgen pathway, leading to hyperandrogenism. So, in contrast to other forms 78 of PAI, the hallmark of classic CAH is not only a decreased concentration of cortisol but also strongly 79 elevated concentrations of precursor steroids and adrenal androgens. Patients with non-classic CAH 80 (NCCAH), a less severe subgroup, generally produce normal concentrations of cortisol but still have 81 elevated concentrations of precursor steroids and androgens [4].

The first step in diagnosing PAI is measuring morning total cortisol concentrations in blood. To evaluate the potential responsiveness of the HPA axis to stress, stimulation tests are performed, such as the insulin tolerance test (ITT) [5] or the Synacthen® test [6]. In these tests, a suboptimal cortisol response is defined as a total cortisol concentration <500 nmol/L (18  $\mu$ g/dL) [7], but there is an ongoing debate on this threshold [8]. In the CAH guideline, the cut-off is defined as <400 – 500 nmol/L (<14 – 18  $\mu$ g/dL), depending on the measuring method [9].

88 Cortisol is in blood mostly bound to proteins (±95%), such as corticosteroid-binding globulin (CBG) 89 and albumin [10, 11]. The measured total cortisol is comprised of the bound and free (i.e., unbound) 90 cortisol, while, according to the free hormone hypothesis, only the latter determines the biological 91 glucocorticoid activity [12]. In addition, patients with 210HD have elevated levels of 17-92 hydroxyprogesterone (170HP) that can be metabolized by 11-hydroxylase into 21-deoxycortisol 93 (21DF) [13]. Interestingly, previous studies have described untreated classic CAH patients with 94 insufficient cortisol production without overt complaints of cortisol deficiency [14-17]. Our group 95 showed that 21DF can transactivate the glucocorticoid receptor with a relative potency of 49% 96 compared to cortisol, the most potent endogenous glucocorticoid. Hence, 21DF contributes to the 97 glucocorticoid activity, especially when the concentration is significantly increased, such as in 98 patients with 210HD [14]. In addition, it is known that precursor steroids can bind to CBG [11, 18, 99 19], thereby competing with cortisol for bindings spots on CBG and preventing cortisol from binding, 100 therewith increasing the free fraction of cortisol. These mechanisms might contribute to the 101 attenuation of symptoms in patients with untreated classic CAH. So far, no studies have been 102 conducted on free cortisol and free 21DF measurements in patients with CAH. Our aim is to quantify 103 total and free concentrations of cortisol and 21DF in the morning and 60 minutes after 104 administration of Synacthen<sup>®</sup> in patients with untreated classic CAH (both 110HD and 210HD). We

105 will compare these results with patients with NCCAH, patients with adrenal insufficiency (AI) but not

106 CAH, and controls to investigate the situation of CAH patients in more detail. We hypothesize that

107 free cortisol and (free) 21DF concentrations might give a better reflection of the glucocorticoid

108 activity in patients with 210HD compared to solely measuring total cortisol levels.

109

### 110 Materials and methods

111 Subjects

112 This study was approved by the local medical ethics committee (Radboudumc, case number 2021-

113 12944). Patients were included via three routes (see Figure S1):

114 (I) Indonesian cohort (n=22): Serum samples from an Indonesian cohort of untreated classic

115 CAH patients (210HD, n=17; 110HD, n=5) were obtained as previously described [14].

116Ethical approval was obtained from the ethical committee of the Faculty of Medicine,117Diponegoro University, Semarang, Indonesia (713/EC/FK-RSDK/2016).

118 (II) Dutch retrospective cohort (n=39): Stored residual serum samples from Synacthen<sup>®</sup> tests
 119 performed between January 2016 and March 2021 were retrospectively collected.

120 (III) Dutch prospective cohort (n=19): Residual serum and plasma samples were obtained
 121 from three hospitals in the Netherlands between April 2021 and January 2024.

122 For the Synacthen<sup>®</sup> tests, blood was obtained before ( $T_0$ ) and 60 minutes after ( $T_{60}$ ) administration of 123 250 µg Tetracosactide. Samples were kept frozen at  $\leq$  -30 °C until analysis. Inclusion criteria were: 124  $\geq$ 300 µL residual serum available and patients not treated with systemic glucocorticoids for at least 125 one year before blood withdrawal. Pseudonymized data about age, gender, time of blood 126 withdrawal, indication of Synacthen® test, and diagnosis were collected. Patients were divided into 127 four groups: (I) patients with classic CAH (both 210HD and 110HD), (II) patients with NCCAH based 128 on 210HD, (III) patients with adrenal insufficiency (AI) but not CAH, and (IV) patients with an optimal 129 cortisol response after Synacthen<sup>®</sup> (controls). Classification of CAH patients in classic CAH and NCCAH 130 was based on clinical characteristics, biochemical evaluation, and genetic analysis (Table S1) [20, 21]. 131 Sequencing results were compared to the reference sequence GenBank NM\_000500.9 for CYP21A2 132 and NM 000497.3 for CYP11B1. In this article the term 'classic CAH' refers to both 210HD and 133 110HD patients.

134

135 Measurement of total steroid concentrations with LC-MS/MS

Total serum 17OHP (17-hydroxypregn-4-ene-3,20-dione), 11-deoxycortisol (17,21-dihydroxypregn-4ene-3,20-dione), 21DF (11,17-dihydroxypregn-4-ene-3,20-dione), and cortisol (11,17,21trihydroxypregn-4-ene-3,20-dione) were analyzed by a clinically validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method on a 6490 triple quadrupole LC-MS/MS (Agilent

140 Technologies, Santa Clara, CA) preceded by protein precipitation and solid phase extraction (SPE). An internal standard mix (20  $\mu$ L in methanol: H<sub>2</sub>O 30:70) containing [<sup>13</sup>C<sub>3</sub>]-17OHP, [<sup>2</sup>H<sub>5</sub>]-11-deoxycortisol, 141  $[{}^{2}H_{a}]$ -21DF, and  $[{}^{13}C_{3}]$ -cortisol (all from Isosciences, Ambler, PA) with concentrations of 10, 10, 20, 142 143 and 100 nmol/L, respectively, was added to 100 µL serum. For protein precipitation, acetonitrile + 144 0.1% formic acid was added and incubated for at least 10 minutes at room temperature and 145 centrifuged (10 min, 5000g). Then, 200  $\mu$ L supernatant was added to 300  $\mu$ L H<sub>2</sub>O followed by SPE 146 using Oasis® HLB 1cc cartridges (Waters Corporation, Milford, MA). These cartridges were 147 preequilibrated with 1 mL methanol: isopropanol (95:5) and consequently washed with 1 mL  $H_2O$ . 148 After sample application, columns were washed with  $1 \text{ mL H}_2\text{O}$  and  $1 \text{ mL methanol:H}_2\text{O}$  (30:70). The eluate (300  $\mu$ L, methanol:isopropanol 95:5) was dried under a stream of N<sub>2</sub> gas at 40 °C, 149 150 reconstituted in 100  $\mu$ L methanol:H<sub>2</sub>O (30:70) and injected (10  $\mu$ L) into an Agilent Technologies 1290 151 Infinity UHPLC-system (Agilent Technologies). LC-MS/MS settings are shown in Table S2. The collision 152 energy was optimized for each analyte and internal standard and two mass transitions (quantitative 153 and qualitative) were monitored. A nine-point calibration curve with 170HP, 11DF, 21DF, and cortisol 154 (all from Sigma-Aldrich, St. Louis, MO, USA) was used for quantification. The calibration ranges were 0 – 167 nmol/L for 170HP, 0 – 191 nmol/L for 11DF, 0 – 167 nmol/L for 21DF, and 0 – 2,299 nmol/L 155 156 for cortisol. In-house quality controls of human serum were measured in duplicate in each run.

157

### 158 Measurement of free steroid concentrations with LC-MS/MS

159 Measurement of free 21DF was incorporated in a clinically validated measuring method for free 160 cortisol and free testosterone. Equilibrium dialysis was performed with samples buffered to pH 7.4 (± 161 0.03) at 37 °C (± 0.5) by a previously described HEPES buffer (4-(2-Hydroxyethyl)piperazine-1-162 ethanesulfonic acid; Merck, Rahway, NJ, USA) that resembled the ionic environment of serum [22]. 163 Two identical volume compartments (180  $\mu$ L) were separated by a semipermeable regenerated 164 cellulose membrane (Serva Electrophoresis GmbH, Heidelberg, Germany) with a diameter of 28 mm 165 and maximum permeability of 5 kDA. During dialysis, cells were placed in a water bath at 37  $^{\circ}$ C (± 0.5) 166 for 5h while continuously rotating. After dialysis, dialysate was emptied from the cell and SPE was 167 performed with 100  $\mu$ L preceded by the addition of H<sub>2</sub>O (30  $\mu$ L) and an internal standard mix (20  $\mu$ L) 168 containing [<sup>2</sup>H<sub>4</sub>]-21DF, [<sup>13</sup>C<sub>3</sub>]-cortisol, and [<sup>13</sup>C<sub>3</sub>]-testosterone (all from IsoSciences). For SPE, Oasis® MCX 1cc cartridges (Waters Corporation) were preequilibrated with 1 mL methanol: isopropanol 169 170 (95:5) and consequently washed with 1 mL H<sub>2</sub>O. After sample application, columns were washed with 1 mL H<sub>2</sub>O + 5% ammonium hydroxide and 1 mL methanol: H<sub>2</sub>O (20:80) + 2% formic acid. The eluate 171 172 (300 µL, 100% methanol) was dried in the Savant<sup>™</sup> SpeedVac<sup>™</sup> Concentrator (ThermoFisher Scientific, Waltham, MA, USA) for  $\pm$  1h, reconstituted in 30 µL methanol:H<sub>2</sub>O (30:70) and injected (10 173 µL) into a Xavi<sup>®</sup> TQ-XS StepWave XS<sup>™</sup> triple quadrupole spectrometer (Waters Incorporation). LC-174

175 MS/MS settings including collision energy and mass transitions are shown in Table S3. A nine-point 176 calibration curve with 21DB (Steraloids, Newport, RI, USA), 21DF, and cortisol (both from Sigma-177 Aldrich) was used for quantification. The calibration ranges were 0 – 115 nmol/L for all three 178 steroids.

179

### 180 Method validation

181 All measurements were performed in an ISO15189 accredited laboratory. All clinically validated 182 measuring methods are monitored for quality in each run using in duplicate measurements of in-183 house quality controls of human serum. For validation, a CLSI EP6 protocol [23] in serum was used to 184 assess linearity. We measured steroid concentrations in a blank sample that was injected after the 185 highest standard to assess carry-over. Ion suppression was measured according to CLSI C62-A 186 guideline [24]: gualitative ion suppression by continuous infusion of the labeled steroid, and 187 quantitative ion suppression by comparing the signal of human serum measurements (n=5) with the signal of spiked prepared matrix-free blank. Imprecision was assessed by a modified CLSI EP5 188 189 protocol [25] with pooled human serum samples at a low (n=7 for 21DF; n=20 for cortisol) and high 190 concentration (n=8 for 21DF, n=20 for cortisol). The lower limit of quantification (LLOQ) was defined 191 as the lowest concentration with an inter-assay coefficient of variation (CV) <20% and was 192 determined with a modified EP evaluator protocol from pooled serum by between-day assay 193 repeated measurements (n=10). For 21DF, recovery was calculated in five samples to which 29.94 194 nmol/L was added. For cortisol, a National Institute of Standards and Technology (NIST) standard 195 (LOT number: 271020) diluted to 1.496 nmol/L was measured each run (n=29). A correction factor of 1.03 was applied to adjust free cortisol levels according to the NIST standard. Possible interfering 196 197 substances were identified by measuring commercially available steroids and anti-androgens with a 198 molecular mass  $\leq 2$  g/mol lower than the analyte or the internal standard. First, retention time 199 interference was checked, and second, MRM transition interference was evaluated.

200

### 201 Data and statistical analyses

202 Free cortisol percentage was calculated by dividing the free cortisol concentration by the total 203 cortisol concentration from the same sample multiplied by 100%. Since cortisol has a diurnal rhythm, 204 only morning samples (between 08.00 - 11.00 AM) were used for the analyses of absolute free and total cortisol concentrations. Results <LLOQ with a signal-to-noise ratio <5 were assigned a value of 205 206 half the LLOQ. These results were excluded from the calculation of percentages. A Kruskal-Wallis test 207 was used to compare means between different subgroups (classic CAH vs NCCAH vs AI vs control). 208 For comparison of related samples ( $T_0$  vs  $T_{60}$ ), a related-samples Wilcoxon signed ranked test was 209 used.

Ъ	1	$\sim$
Z	т	υ

#### 211 Results

212 Subjects

In total, data from 22 Indonesian and 58 Dutch patients were collected, see Figure S1 for the inclusion flowchart. Patients with an insufficient volume of residual material (n=31) and patients treated with glucocorticoids before the test were excluded (n=1). In total, 48 patients were divided into four groups: classic CAH (n=29; 210HD [n=24] and 110HD [n=5]), NCCAH (n=5), AI (n=3), and controls (n=11). Demographics of included patients are shown in Table 1.

218

### 219 Method validation

220 An LC-MS/MS method for free cortisol and free 21DF was established and validated. The 221 measurement of 21DF was linear between 0.13 and 99.2 nmol/L and the measurement of free 222 cortisol was linear between 0.08 and 66 nmol/L. The maximum deviation from linearity, imprecision, 223 LLOQ, recovery, and ion suppression are shown in Table 2. Carry-over was negligible for both 224 components. For cortisol and its internal standard, we evaluated 18-hydroxycorticosterone as 225 possible interfering substance and it showed no interference. For 21DF and its internal standard, 226 corticosterone, 11-deoxycortisol, and 18-hydroxy-11-deoxycorticosterone were evaluated and 227 showed no interference.

228

# 229 <u>Baseline</u>

230 Morning free cortisol levels in classic CAH patients are similar to levels in controls at T<sub>0</sub>

The median total cortisol concentration in the morning (samples at  $T_0$ ) was 106 nmol/L in the untreated classic CAH patients, which was significantly lower than NCCAH patients (249 nmol/L, p=0.010) and controls (202 nmol/L, p=0.016) (Figure 1A).

Interestingly, the median *free* morning cortisol concentration in untreated classic CAH patients (8.62 nmol/L) was not significantly different from NCCAH patients (9.84 nmol/L, p=0.313) and controls (6.94 nmol/L, p=0.573) (Figure 1B). So, in contrary to the total cortisol concentrations, this suggests a comparable availability of cortisol in our classic CAH cohort compared to NCCAH patients and controls.

In untreated classic CAH patients, the concentration of free cortisol is higher than expected based on
the total cortisol concentration. This is also indicated by the percentage of free cortisol, which was
7.5% for classic CAH patients, significantly higher than free cortisol percentages of NCCAH patients
(5.5%, p=0.025), AI patients (2.1%, p<0.001), and controls (3.3%, p<0.001) (Figure S2A).</li>

243

244 Patients with 210HD have increased total 21DF concentrations compared to AI patients and controls

Patients with 210HD have increased total 21DF concentrations with a median of 67.5 nmol/L at T<sub>0</sub>.
This was significantly higher compared to all other groups: NCCAH patients had a median of 3.03
nmol/L (p=0.020), and total 21DF concentrations in AI patients and controls were all <LLOQ (0.7</li>
nmol/L) (p<0.001) (Figure 1C).</li>

For *free* 21DF concentrations at T<sub>0</sub>, the same is observed: the median concentration in 21OHD patients (5.32 nmol/L) was significantly higher compared to median levels in NCCAH patients (0.34 nmol/L; p=0.025), AI patients (<0.19 nmol/L, (p=0.003), and controls (<0.19 nmol/L, p<0.001) (Figure 1D).

253

In all 110HD patients, total and free 21DF concentrations were <LLOQ (data not shown).

255

256 After Synacthen® stimulation

257 Patients with classic CAH have lower (free) cortisol concentrations T<sub>60</sub> compared to controls

258 All controls had a total cortisol concentration ≥500 nmol/L at T<sub>60</sub> (median 658 nmol/L), indicating 259 sufficient cortisol production during stress according to current guidelines [7]. In NCCAH patients, 260 total cortisol concentrations increased with a median of 42% (p=0.043), although not with the same 261 steep increase as observed in controls (198%; p=0.005). In none of the NCCAH patients the 500 262 nmol/L threshold (median 402 nmol/L) was reached, but 60% (3/5) of them reached the 400 nmol/L 263 threshold as proposed in the CAH guideline [9]. In the remaining two NCCAH patients, stimulated 264 total cortisol concentrations of 305 and 397 nmol/L were measured. Total cortisol concentrations did 265 not increase upon Synacthen<sup>®</sup> administration in classic CAH and AI patients (p=0.466 and p=0.655, 266 respectively) (Figure 2A). Classic CAH (median 119 nmol/L) and AI patients (median 172 nmol/L) did 267 both not reach the 500 nmol/L threshold [7] nor the 400 nmol/L threshold [9], indicating adrenal 268 insufficiency, as expected in these patients.

269 The free cortisol concentration increased after Synacthen® administration in classic CAH patients by 270 10.7% (p=0.001). In NCCAH patients and controls, we observed a median increase of 144% (p=0.043) 271 and 610% (p=0.005), respectively. No significant increase in the free cortisol concentration was 272 observed in AI patients (p=0.655) (Figure 2B). At  $T_{60}$ , the median *free* cortisol concentration in classic 273 CAH patients was 9.85 nmol/L, which was significantly lower compared to levels in NCCAH patients 274 (33.8 nmol/L, p=0.010) and controls (63.6 nmol/L, p<0.001), but not significantly different from AI 275 patients (5.08 nmol/L, p=0.377) (data not shown). In all controls, an increase of free cortisol  $\geq$ 37 276 nmol/L after stimulation was measured. Levels of free cortisol after Synacthen® stimulation in 277 NCCAH patients ranged from 22 to 45 nmol/L. Patients with classic CAH did not reach serum levels of 278 free cortisol seen in controls after Synacthen<sup>®</sup> (maximum 21.8 nmol/L).

After Synacthen<sup>®</sup>, the *percentage of free cortisol* increased in classic CAH (p=0.001), NCCAH (p=0.043), and control patients (p=0.005), but not in AI patients (p=0.655) (Figure S2B). At T<sub>60</sub>, the median free cortisol percentage of classic CAH patients (8.9%) was significantly higher compared to AI patients (2.9%, p=0.019) but not significantly different from NCCAH patients (7.4%, p=0.235) and controls (9.7%, p=0.520) (Figure S2C).

284

285 Concentrations of free 21DF increase after Synacthen® administration in classic 210HD patients

The total 21DF concentration significantly increased upon ACTH stimulation in NCCAH patients (p=0.043), but not in classic 210HD patients (p=0.121) (Figure 2C). At  $T_{60}$ , the median total 21DF concentrations in classic 210HD and NCCAH patients were 94.6 nmol/L and 26.4 nmol/L, respectively. The total 21DF concentration in AI patients remained <LLOQ at  $T_{60}$ . In controls, the maximum total 21DF concentration was twice the LLOQ (0.7 nmol/L) for two patients. The 210HD patients had significantly higher total 21DF concentrations at  $T_{60}$  compared to AI patients (p=0.005) and controls (p<0.001) (data not shown).

The free 21DF concentration significantly increased in both classic CAH (p=0.023) and NCCAH patients (p=0.043) (Figure 2D). At  $T_{60}$ , the median free 21DF concentration was 7.34 nmol/L in classic CAH patients and 2.22 nmol/L in NCCAH patients (p=0.054). For all AI patients, the free 21DF concentration was <LLOQ at  $T_{60}$ . Controls had a median of 0.18 nmol/L free 21DF at  $T_{60}$  (data not shown). In all 110HD patients, total and free 21DF concentrations were <LLOQ (data not shown).

298 In classic 210HD patients, the percentage of free 21DF was 8.4% at  $T_0$  which significantly increased to 299 10.3% (p=0.035) at  $T_{60}$ . For NCCAH patients, there was no significant increase in the percentage of 300 free 21DF after ACTH stimulation, it was 8.8% both at  $T_0$  and  $T_{60}$  (data not shown).

301

#### 302 Discussion

303 In this study, we evaluated for the first time the concentrations of free cortisol and free 21DF in a 304 group of untreated patients with classic CAH (both 210HD and 110HD), NCCAH, other forms of AI, 305 and controls. We found that the *free* cortisol concentration in untreated classic CAH patients is 306 similar to the concentration in controls in the unstimulated situation, despite decreased total cortisol 307 levels. This could explain why some patients with classic 210HD or 110HD show no or only mild 308 symptoms of cortisol deficiency in the basal situation. In addition, patients with classic 210HD have 309 elevated concentrations of total and free 21DF, which is not observed in AI patients and controls, 310 increasing the glucocorticoid activity. After Synacthen®, classic CAH patients show no increase in 311 their total cortisol levels and only a minimal increase in free cortisol levels, but we measured 312 increased free levels of the glucocorticoid 21DF in 210HD patients. This might explain why these 313 patients survived periods of severe stress without glucocorticoid treatment.

For this study, we have developed an LC-MS/MS method to measure free cortisol and free 21DF. The mean free cortisol percentage in our control group (3.7%) was similar to the percentage found by others (3.95%) [26, 27]. We observed that the relative increase in free cortisol concentration (610%) after Synacthen<sup>®</sup> administration was higher compared to the relative increase in total cortisol (198%), which was also observed in other studies [26-28]. Therefore, evaluating free concentrations may be more informative than evaluating total concentrations.

320 Glucocorticoids exert a plethora of functions in the human body, and they are especially necessary 321 during periods of stress. Therefore, two situations should be distinguished when interpreting 322 glucocorticoid levels: the daily baseline situation and an episode with physical stress.

323

### 324 Baseline situation

325 Cortisol in blood is mostly bound to CBG and albumin, but only its free form is biologically active 326 according to the free hormone hypothesis [29]. We found that in the baseline situation, total cortisol 327 concentrations of untreated classic CAH patients are lower compared to controls, but free cortisol 328 concentrations were similar. This is supported by data from Waaijers et al., that found cortisol 329 concentrations within the reference range in hair of untreated classic CAH patients [30], suggesting 330 similar long-term free cortisol levels between classic CAH patients and the reference population. This 331 might be explained by several hypotheses: (I) In classic CAH patients, increased levels of structurally 332 analogous steroids, such as 170HP and 21DF, may disrupt or prevent cortisol from binding to CBG or 333 albumin [11, 18, 19], leading to a higher percentage of free cortisol; (II) CAH patients have increased 334 concentrations of adrenal androgens, which are known to decrease 11β-hydroxy steroid 335 dehydrogenase type 2 activity, preventing the conversion of active cortisol into inactive cortisone 336 [31]; (III) androgens are able to decrease CBG levels, thereby possibly increasing the free cortisol 337 concentrations [32, 33].

338 In addition, we found that in the basal situation, classic 210HD patients have increased 21DF 339 concentrations, which confirms the findings of previous studies [34-36]. Our group showed that 21DF 340 has a relative potency of 49% to activate the glucocorticoid receptor compared to cortisol [14]. The 341 median free 21DF concentration in untreated classic CAH patients of 5.32 nmol/L would be 342 equivalent to (0.49 x 5.32 =) 2.61 nmol/L cortisol. Hypothetically this adds to the glucocorticoid 343 activity of classic 210HD patients. So, these patients have more glucocorticoid activity than expected 344 based on their total cortisol levels. This could explain why some classic CAH patients have lived 345 without glucocorticoid medication during daily circumstances. Patients with 110HD are not capable 346 of producing 21DF, but their free cortisol levels were already similar to controls.

347

348 During periods of stress

349 During periods of physical stress, such as illness or surgery, there is a higher demand for 350 glucocorticoids. Classic CAH patients were not able to increase their total cortisol levels after ACTH 351 stimulation. In our study untreated classic CAH patients did not reach the 400-500 nmol/L total 352 cortisol threshold after Synacthen<sup>®</sup> administration [9]. We found only a small increase in free cortisol 353 levels, but classic CAH patients did not reach the increase in free cortisol levels of the control group. 354 Interestingly, we did observe an increase in the free concentration of the glucocorticoid 21DF in 355 patients with 210HD up to a median of 7.34 nmol/L. Given that 21DF is capable of activating the 356 glucocorticoid receptor these increased concentrations may contribute significantly to the 357 glucocorticoid activity. However, it is questionable if this concentration of free glucocorticoids is 358 enough to reach sufficient glucocorticoid activity in these patients during periods of stress to prevent 359 Addisonian crisis. Therefore, it is still not entirely clear how previously described untreated classic 360 210HD patients have survived periods of physical stress, such as dengue fever and surgery, without 361 glucocorticoid treatment [14-17]. Other protective measures might be important in these patients 362 during stress episodes. Kroon et al. have reviewed that androgens can also contribute to the 363 glucocorticoid activity either by direct binding to the glucocorticoid responsive elements or by 364 assisted loading [31], in which androgen signal transduction opens the chromatin, enabling activated 365 glucocorticoid receptors to bind the responsive elements and enhance glucocorticoid signaling. In 366 addition, Hamrahian et al. showed that the percentage of free cortisol increases in healthy 367 individuals after administration of synthetic ACTH [29]. The continuous ACTH pressure in classic CAH 368 patients might also directly increase the free cortisol percentage, leading to more free cortisol and 369 hence more glucocorticoid activity. It would be interesting to further investigate these hypotheses in 370 the specific situations of patients with CAH.

371

#### 372 Indication for glucocorticoid treatment

373 Previously, we and others described classic CAH patients who have survived without glucocorticoid 374 treatment despite low total cortisol levels and the inability to increase total cortisol levels during 375 stress [14-17]. The similar concentration of free cortisol in untreated classic CAH patients compared 376 to controls might explain this clinical observation. Intriguingly, in clinical practice, some classic CAH 377 patients -mostly males and 46,XX individuals living as males- exhibit so few overt signs of adrenal 378 cortex insufficiency that they refuse glucocorticoid medication [37, 38]. However, patients have to be 379 counseled about the potential risks of being untreated; Besides the risk to develop an Addisonian 380 crisis, elevated ACTH levels can lead to the development of testicular adrenal rest tumors and 381 adrenal myelolipomas [37]. Furthermore, elevated levels of androgens and precursor steroids may 382 contribute to an unfavorable cardiovascular risk profile [39].

Genotype-phenotype correlations in CAH are not always accurate. In our study, we also found a discrepancy between the expected phenotype based on genetics and the clinical phenotype, especially for the R356W mutation in the *CYP21A2* gene. Stoupa *et al.* [40] reported that 60% of their NCCAH patients had an inadequate cortisol response after Synacthen<sup>®</sup>, while none of them experienced periods of cortisol deficiency, highlighting that not all patients with an insufficient total cortisol concentrations have clinically relevant adrenal cortex insufficiency.

389

Our findings suggest that measuring total cortisol levels alone may not be the most appropriate way to assess adrenal cortex function in all forms of PAI. Supplementary measurement of free cortisol may provide a more accurate reflection of glucocorticoid activity. In 210HD patients, the concentration of (free) 21DF should also be considered to comprehensively evaluate the glucocorticoid activity. This would be especially useful in patients with milder forms of CAH, to indicate the necessity of glucocorticoid treatment. More research is necessary to compute cut-off values for defining adrenal cortex insufficiency and to incorporate it in clinical practice.

Measuring free cortisol levels is not only useful for CAH patients, but also for patients with other conditions in which there is a discrepancy between free and total cortisol levels, for instance patients with hypoproteinemia during critical illness [29], patients with CBG-deficiency [10], or patients who use oral contraceptive medication [41].

401

402 Our study has several strengths and limitations. This is the first study that quantified free cortisol and 403 free 21DF concentrations in untreated classic CAH patients. We did not only compare levels with 404 controls but also with patients with NCCAH and AI. Another strength is the use of a state-of-the-art 405 dialysis method to obtain free concentrations followed by a sensitive LC-MS/MS method, which is the gold standard for steroid measurements in serum [9]. Furthermore, deuterium or <sup>13</sup>C-isotopes of 406 407 each steroid were used as internal standards to allow for the correction of matrix effects. Moreover, 408 all included CAH patients were genetically confirmed. A limitation of our study is the small sample 409 size of the study groups, especially AI patients. PAI is rare and the volume of residual serum was not 410 always sufficient to perform the measurements. Cortisol has a diurnal rhythm, but not all samples 411 were taken in the morning. To correct for this, we only included measurements before 11.00 am in 412 the analyses for total and free cortisol.

413

To conclude, untreated classic CAH patients have free cortisol concentrations in the same range as controls under basal conditions. Moreover, patients with 210HD have an increased production of total and free 21DF, a precursor steroid with glucocorticoid activity. Both mechanisms might explain the low occurrence or lack of symptoms of adrenal insufficiency in daily situations in some untreated

- 418 classic CAH patients. During periods of stress, (free) 21DF concentrations increase in 210HD patients,
- in contrast to patients with other forms of PAI, with probably additional protective effects. Future
- 420 research should focus on the role of free cortisol and free precursor steroids, especially in milder
- 421 forms of CAH to accurately assess the glucocorticoid activity and indicate the necessity of
- 422 glucocorticoid treatment.
- 423

#### 424 References

- Whitworth, J.A., D. Saines, and B.A. Scoggins, *Blood pressure and metabolic effects of cortisol and deoxycorticosterone in man.* Clin Exp Hypertens A, 1984. 6(4): p. 795-809.
- 427 2. Cain, D.W. and J.A. Cidlowski, *Immune regulation by glucocorticoids*. Nat Rev Immunol, 2017.
  428 17(4): p. 233-247.
- 429 3. Elverson, C.A. and M.E. Wilson, *Cortisol: Circadian Rhythm and Response to a Stressor*.
  430 Newborn and Infant Nursing Reviews, 2005. 5(4): p. 159-169.
- 431 4. Adriaansen, B.P.H., et al., *Challenges in treatment of patients with non-classic congenital*432 *adrenal hyperplasia*. Front Endocrinol (Lausanne), 2022. 13: p. 1064024.
- Fraser, R., F. Albright, and P.H. Smith, *The Value of the Glucose Tolerance Test, the Insulin Tolerance Test, and the Glucoseinsulin Tolerance Test in the Diagnosis of Endocrinologic Disorders of Glucose Metabolism1*. The Journal of Clinical Endocrinology & Metabolism, 1941.
  1(4): p. 297-306.
- 437 6. Thorn, G.W., P.H. Forsham, and et al., *The use of adrenocorticotropin as a test of adrenal* 438 *cortical reserve.* J Clin Endocrinol Metab, 1948. **8**(7): p. 589.
- 4397.Bornstein, S.R., et al., Diagnosis and Treatment of Primary Adrenal Insufficiency: An440Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 2016. 101(2): p. 364-44189.
- Reynolds, R.M., et al., Assessing the HPA axis in patients with pituitary disease: a UK survey.
  Clin Endocrinol (Oxf), 2006. 64(1): p. 82-5.
- Speiser, P.W., et al., Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase
  Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 2018.
  103(11): p. 4043-4088.
- Lewis, J.G., et al., *Plasma free cortisol fraction reflects levels of functioning corticosteroid- binding globulin*. Clin Chim Acta, 2005. **359**(1-2): p. 189-94.
- 449 11. Meyer, E.J., et al., Pyrexia and acidosis act independently of neutrophil elastase reactive
  450 center loop cleavage to effect cortisol release from corticosteroid-binding globulin. Protein
  451 Sci, 2020. 29(12): p. 2495-2509.
- 452 12. Mendel, C.M., *The free hormone hypothesis: a physiologically based mathematical model.*453 Endocr Rev, 1989. **10**(3): p. 232-74.
- 45413.Claahsen-van der Grinten, H.L., et al., Congenital Adrenal Hyperplasia-Current Insights in455Pathophysiology, Diagnostics, and Management. Endocr Rev, 2022. 43(1): p. 91-159.
- 456 14. Engels, M., et al., *Glucocorticoid Activity of Adrenal Steroid Precursors in Untreated Patients*457 With Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab, 2019. **104**(11): p. 5065-5072.
- 45815.Speiser, P.W., et al., Aldosterone synthesis in salt-wasting congenital adrenal hyperplasia459with complete absence of adrenal 21-hydroxylase. N Engl J Med, 1991. **324**(3): p. 145-9.
- 460 16. Utari, A., et al., Challenges in the treatment of late-identified untreated congenital adrenal
  461 hyperplasia due to CYP11B1 deficiency: Lessons from a developing country. Front Endocrinol
  462 (Lausanne), 2022. 13: p. 1015973.
- 463 17. Aveiro-Lavrador, M., et al., *Late diagnosis of classic congenital adrenal hyperplasia: long-term* 464 *consequences during adulthood.* Endocrinol Diabetes Metab Case Rep, 2021. 2021.

- 46518.de Moor, P., R. Deckx, and O. Steeno, Influence of various steroids on the specific binding of466cortisol. J Endocrinol, 1963. 27: p. 355-6.
- 467 19. Dunn, J.F., B.C. Nisula, and D. Rodbard, *Transport of steroid hormones: binding of 21*468 *endogenous steroids to both testosterone-binding globulin and corticosteroid-binding*469 *globulin in human plasma*. J Clin Endocrinol Metab, 1981. 53(1): p. 58-68.
- 470 20. Baumgartner-Parzer, S., M. Witsch-Baumgartner, and W. Hoeppner, *EMQN best practice*471 *guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency*. Eur J Hum
  472 Genet, 2020. 28(10): p. 1341-1367.
- 473 21. Krone, N. and W. Arlt, *Genetics of congenital adrenal hyperplasia*. Best Pract Res Clin
  474 Endocrinol Metab, 2009. 23(2): p. 181-92.
- 475 22. Jansen, H.I., et al., Description and validation of an equilibrium dialysis ID-LC-MS/MS
  476 candidate reference measurement procedure for free thyroxine in human serum. Clin Chem
  477 Lab Med, 2023.
- 478 23. McEnroe, R.J., et al., *Evaluation of Linearity of Quantitative Measurement Procedures EP06*.
  479 2020, Clinical and Laboratory Standards Institute.
- 480 24. Clarke, W., et al., *Liquid Chromatography-Mass Spectrometry Methods; Approved Guideline* 481 *C62-A* Vol. 34. 2014: Clinical and Laboratory Standards Institute.
- 482 25. McEnroe, R.J., et al., *Evaluation of Precision of Quantitative Measurement Procedures EP05*. 3
  483 ed. Vol. 34. 2014: Clinical and Laboratory Standards Institute.
- 484 26. Eyal, O., et al., *Establishing Normal Ranges of Basal and ACTH-Stimulated Serum Free Cortisol*485 *in Children*. Horm Res Paediatr, 2016. **86**(2): p. 94-99.
- 486 27. Rauschecker, M., et al., *Cosyntropin-Stimulated Serum Free Cortisol in Healthy, Adrenally*487 *Insufficient, and Mildly Cirrhotic Populations.* J Clin Endocrinol Metab, 2016. **101**(3): p. 1075488 81.
- Vogeser, M., J. Briegel, and R. Zachoval, *Dialyzable free cortisol after stimulation with Synacthen*<sup>®</sup>. Clinical Biochemistry, 2002. **35**(7): p. 539-543.
- 49129.Hamrahian, A.H., T.S. Oseni, and B.M. Arafah, Measurements of serum free cortisol in492critically ill patients. N Engl J Med, 2004. **350**(16): p. 1629-38.
- 49330.Waaijers, S., et al., Measuring steroids in hair opens up possibilities to identify congenital494adrenal hyperplasia in developing countries. Clin Endocrinol (Oxf), 2023. **98**(1): p. 41-48.
- 495 31. Kroon, J., A.M. Pereira, and O.C. Meijer, *Glucocorticoid Sexual Dimorphism in Metabolism:*496 *Dissecting the Role of Sex Hormones.* Trends Endocrinol Metab, 2020. **31**(5): p. 357-367.
- 497 32. Murphy, B.E.P., Corticosteroid-Binding Globulin (Transcortin), in Encyclopedia of Stress, G.
  498 Fink, Editor. 2007, Academic Press. p. 605-613.
- 33. Dickinson, P., et al., *Effects of testosterone treatment on plasma proteins and amino acids in*500 *men.* J Clin Endocrinol Metab, 1969. **29**(6): p. 837-41.
- 50134.Fiet, J., et al., A Liquid Chromatography/Tandem Mass Spectometry Profile of 16 Serum502Steroids, Including 21-Deoxycortisol and 21-Deoxycorticosterone, for Management of503Congenital Adrenal Hyperplasia. J Endocr Soc, 2017. 1(3): p. 186-201.
- 504 35. Fiet, J., et al., Comparison of basal and adrenocorticotropin-stimulated plasma 21505 deoxycortisol and 17-hydroxyprogesterone values as biological markers of late-onset adrenal
  506 hyperplasia. J Clin Endocrinol Metab, 1988. 66(4): p. 659-67.
- 50736.Turcu, A.F., et al., Profiles of 21-Carbon Steroids in 21-hydroxylase Deficiency. J Clin508Endocrinol Metab, 2015. 100(6): p. 2283-90.
- 50937.Engels, M., et al., Testicular Adrenal Rest Tumors: Current Insights on Prevalence,510Characteristics, Origin, and Treatment. Endocr Rev, 2019. **40**(4): p. 973-987.
- 51138.Adriaansen, B.P.H., et al., 46,XX males with congenital adrenal hyperplasia: A clinical and512biochemical description. Unpublished data (under review), 2024.
- 51339.Chistiakov, D.A., et al., Role of androgens in cardiovascular pathology. Vasc Health Risk514Manag, 2018. 14: p. 283-290.

- 515 40. Stoupa, A., et al., *Inadequate cortisol response to the tetracosactide (Synacthen®) test in non-*516 *classic congenital adrenal hyperplasia: an exception to the rule?* Horm Res Paediatr, 2015.
- 517 **83**(4): p. 262-7.
- 518 41. Burke, C.W., *Biologically active cortisol in plasma of oestrogen-treated and normal subjects.*519 Br Med J, 1969. 2(5660): p. 798-800.

520 521

# 522 Table and figure legends

523	Table 1 Demographics of included patients. Continuous data is given as median (IQR).				
524					
525	Table 2 Linearity, Imprecision (within and between day) on low and high level, lower limit of quantification				
526	(LLOQ), recovery, and ion suppression for free 21DF and free cortisol measured by LC-MS/MS after dialysis.				
527					
528	Figure 1 Total and free cortisol and 21DF concentrations (nmol/L) at T0 in patients with classic congenital				
529	adrenal hyperplasia (CAH), non-classic congenital adrenal hyperplasia (NCCAH), adrenal insufficiency but not				
530	CAH (AI), and controls. (A) Morning (8.00 – 11.00 AM) concentrations of total cortisol; (B) Morning				
531	concentrations of free cortisol; (C) total 21DF concentrations (D) Free 21DF concentrations. n.s. non-significant,				
532	*p≤0.05, ** p≤0.01, ***p≤0.001.				
533					
534	Figure 2 Increase of total and free cortisol and 21DF concentrations (nmol/L) before (TO) and after (T60)				
535	Synacthen® in patients with classic congenital adrenal hyperplasia (CAH), non-classic congenital adrenal				
536	hyperplasia (NCCAH), adrenal insufficiency but not CAH (AI), and controls. (A) Change in total cortisol				
537	concentrations; (B) Change in free cortisol concentrations; (C) Change in total 21DF concentrations; (D) Change				
538	in free 21DF concentrations. *p≤0.05, ** p≤0.01, ***p≤0.001.				

539

	САН	NCCAH	AI	Control
Number (n)	29	5	3	11
Age (years)	13.2	8.9	16.1	9.8
	(3.3 – 19.6)	(6.0 - 18.7)	(11.8 – 17.3)	(7.9 – 14.7)
Genotype (% 46,XY)	10.3	40.0	33.3	63.6
Sex (% males)	41.4	40.0	33.3	63.6
Diagnosis / Indication for Synacthen <sup>®</sup> test	CAH (100%)	NCCAH (100%)	X-ALD (33.3%) AD (33.3%) Unknown (33.3%)	Screening X-ALD (18%) Premature pubarche (18%) Screening hypothyroidism (18%) Fatigue (9%) Collapse and hypotension (9%) Screening MEN-1 (9%) Papid postnatal growth (9%)

Гabl	e 1	Demograpl	hics of	<sup>:</sup> included	l patients.	Continuous d	lata is given a.	s median (	'IQR,	).
------	-----	-----------	---------	-----------------------	-------------	--------------	------------------	------------	-------	----

Rapid postnatal growth (9%) Once measured low cortisol (9%)

	Free 21DF	Free Cortisol
Linearity		
Linearity range (nmol/L)	0.13 – 99.2	0.08 – 66.0
Deviation from linearity (%)	1.55	0.96
Imprecision low		
Concentration (nmol/L)	0.36	11.4
Within day (%)	2.8	2.6
Between day (%)	8.5	4.6
Imprecision high		
Concentration (nmol/L)	4.89	104.4
Within day (%)	3.3	2.5
Between day (%)	2.8	4.0
LLOQ (nmol/L)	0.19	<0.32*
Recovery		
Concentration (nmol/L)	29.94	1.496
Average recovery (%)	108	97.3
lon suppression (%)	<1	<1

Table 2 Linearity, Imprecision (within and between day) on low and high level, lower limit of quantification(LLOQ), recovery, and ion suppression for free 21DF and free cortisol measured by LC-MS/MS after dialysis.Free 21DFFree Cortisol

\*mean CV of 6.1%



CAH NCCAH AI Control







CAH NCCAH AI Control

